321 HARRISON AVENUE, BOSTON, MA
Reports Second Quarter 2025 Financial Results and Provides Business Update
Other Events
Changes in Board, Management or Compensation
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Business Update
Investor Presentation
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership